Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PA452 is a selective antagonist of retinoic X receptor (RXR) and suppresses the effect of Retinoic acid on Th1/Th2 development.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 84.00 | |
5 mg | In stock | $ 263.00 | |
10 mg | In stock | $ 423.00 | |
25 mg | In stock | $ 692.00 | |
50 mg | In stock | $ 986.00 | |
100 mg | In stock | $ 1,350.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 288.00 |
Description | PA452 is a selective antagonist of retinoic X receptor (RXR) and suppresses the effect of Retinoic acid on Th1/Th2 development. |
In vitro | PA452 suppresses the Troglitazone (TZ)-induced CK13 expression. In normal human urothelial (NHU) cells, PA452 (0.01-1 μM) inhibits retinoic X receptor[2]. |
Molecular Weight | 439.59 |
Formula | C26H37N3O3 |
CAS No. | 457657-34-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 4.4 mg/mL (10.01 mM), sonification/heating is recommended.
DMSO: 36mg/mL (81.9mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PA452 457657-34-0 Metabolism Retinoid Receptor RAR/RXR PA 452 PA-452 inhibitor inhibit